El Nasr Manufacturing Agricultural Crops S.A.E (EGX:ELNA)

Intra-Cellular Therapies Income Statement

Financials in millions EGP. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Selling, General & Admin	3.3	2.52	4.07	3.89	3.86
Other Operating Expenses	-1.21	-0.14	-0.08	1.61	-0.13
Operating Expenses	2.09	2.38	4	5.5	3.74
Operating Income	-2.09	-2.38	-4	-5.5	-3.74
Interest & Investment Income	0.01	0.02	-	0.01	0.01
Other Non Operating Income (Expenses)	0	-0.01	-	-	-
EBT Excluding Unusual Items	-2.08	-2.37	-4	-5.49	-3.73
Gain (Loss) on Sale of Assets	-	-	-0.13	0.12	-0.6
Pretax Income	-2.08	-2.37	-4.13	-5.37	-4.33
Income Tax Expense	0.26	0.26	-	-	-0.07
Net Income	-2.34	-2.63	-4.13	-5.37	-4.25
Net Income to Common	-2.34	-2.63	-4.13	-5.37	-4.25
Shares Outstanding (Basic)	8	8	8	8	8
Shares Outstanding (Diluted)	8	8	8	8	8
EPS (Basic)	-0.30	-0.33	-0.52	-0.68	-0.54
EPS (Diluted)	-0.30	-0.33	-0.52	-0.68	-0.54
Free Cash Flow	0.06	-0	-0.1	-0.22	-0.3
Free Cash Flow Per Share	0.01	-	-0.01	-0.03	-0.04
EBITDA	-1.43	-1.72	-3.35	-4.85	-3.08
D&A For EBITDA	0.66	0.66	0.65	0.65	0.66
EBIT	-2.09	-2.38	-4	-5.5	-3.74

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.